

ERRATUM

KARLOVA UNIVERZITA V PRAZE
FARMACEUTIKÁ FAKULTA V HRADCI KRÁLOVÉ
KATEDRA SOCIÁLNÍ A KLINICKÉ FARMACIE

**Pilotní studie lékové adherence nemocných trpících
ulcerózní kolitidou**

(Diplomová práce)

Konstantina Tsianou

Školitel Diplomová práce:

Prof. RNDr. Jiří Vlček, CSc

CONTENTS

Contents

| | |
|---|-----------|
| INTRODUCTION AND AIM OF DIPLOMA THESIS..... | 4 |
| List of abbreviations..... | 6 |
| PART A: THEORITICAL | |
| CHAPTER 1: <i>Ulcerative Colitis</i>..... | 7 |
| 1.1 Etiopathology..... | 7 |
| 1.1.1 Etiology..... | 7 |
| 1.1.2 Pathology..... | 12 |
| 1.2 Clinical Features..... | 14 |
| 1.2.1 Symptoms..... | 15 |
| 1.2.2 Signs..... | 17 |
| 1.2.3 Laboratory Findings..... | 17 |
| 1.3 Diagnosis..... | 18 |
| 1.3.1 Diagnostic Methods..... | 18 |
| 1.3.2 Diagnostic Factors..... | 21 |
| 1.3.3 Differential Diagnosis..... | 24 |
| 1.4 Treatment..... | 25 |
| 1.4.1 Medical Treatment..... | 25 |
| 1.4.2 Surgical Treatment..... | 26 |
| 1.5 Assessment of Clinical Severity..... | 27 |
| 1.6 Management according to clinical severity..... | 27 |
| 1.6.1 Management of mild to moderate ulcerative colitis..... | 27 |
| 1.6.2 Management of severe ulcerative colitis..... | 28 |
| CHAPTER 2: <i>Medical Treatment of Ulcerative Colitis</i>..... | 29 |
| 2.1 Aminosalicylates..... | 29 |
| 2.1.1 Oral..... | 29 |
| 2.1.2 Topical..... | 32 |
| 2.2 Glucocorticoids..... | 33 |
| 2.2.1 Systemic..... | 33 |
| 2.2.2 Topical..... | 34 |
| 2.3 Immunomodulators..... | 35 |
| 2.3.1 Azathioprine and 6-Mercaptopurine..... | 35 |
| 2.3.2 Cyclosporine..... | 39 |
| 2.3.3 Methotrexate..... | 40 |
| 2.3.4 Other Immunomodulators..... | 41 |
| 2.4 Antibiotics..... | 42 |
| 2.5 Probiotics, Prebiotics and Synbiotics..... | 42 |
| 2.6 Biological Therapy..... | 43 |
| CHAPTER 3: <i>Adherence of drug compliance measurements</i>..... | 46 |
| 3.1 The multifactorial nature of adherence..... | 46 |

| | |
|---|-----|
| 3.2 Strategies for adherence improvement..... | 47 |
| 3.3 Methods for Adherence measurement..... | 48 |
| 3.4 Self-administered questionnaires for adherence measurement..... | 51 |
| CHAPTER 4: <i>The Belief about Medicine Questionnaire (BMQ); Pharmacotherapy</i> | 59 |
| 4.1 Beliefs about Medicine Questionnaire description..... | 59 |
| 4.2 BMQ in chronic Conditions..... | 60 |
| 4.3 BMQ in GastroIntestinal Diseases..... | 62 |
| 4.4 BMQ experience in Greek IBD patients..... | 67 |
| 4.5 Pharmacotherapy..... | 75 |
| PART B: EXPERIMENTAL | |
| CHAPTER 5: <i>BMQ in UC patients</i> | 78 |
| 5.1 Patients Cohort..... | 78 |
| 5.2 Study Protocol..... | 78 |
| 5.3 Statistical analysis & Obtained Results..... | 79 |
| CHAPTER 6: <i>Discussion and Conclusions</i> | 88 |
| REFFERENCES | 94 |
| ABSTRACT in English | 105 |
| ABSTRACT in Czech | 106 |
| APPENDIX | 107 |

LIST OF TABLES AND FIGURES

TABLES

| | |
|--|----|
| Table I: Medication Adherence Rating Scale (MARS)..... | 51 |
| Table II: Trust in Physician Scale..... | 52 |
| Table III: Hospital Anxiety and Depression Scale (HADS)..... | 52 |
| Table IV: Belief about Medicine Questionnaire (BMQ)..... | 53 |
| Table V: Work Productivity and Activity Impairment Questionnaire: Crohn's Disease (WPAI-CD)..... | 53 |
| Table VI: Crohn Colitis Knowledge Score..... | 55 |
| Table VII: Short Inflammatory Bowel Disease Questionnaire (short-IBDQ)..... | 56 |
| Table VIII: Simple Clinical Colitis Activity Index (SCCAI)..... | 57 |
| Table IX: Several works with translated of BMQ..... | 62 |
| Table X: Employing BMQ in GI..... | 65 |
| Table XII. Frequency analysis of the demographic characteristics..... | 68 |
| Table XIII. Descriptive statistics of the demographic characteristics..... | 69 |
| Table XIV. Data adequacy for factor analysis..... | 70 |
| Table XV. Confirmatory factor analysis of the BMQ factor subscales..... | 70 |
| Table XVI. Descriptive statistics of the BMQ factor subscales..... | 71 |
| Table XVII. Internal validity of the BMQ factor subscales..... | 72 |
| Table XVIII. Pearson's correlation coefficient between the BMQ factor subscales..... | 72 |
| Table XIX. Univariate associations between demographic characteristics and the BMQ factor subscales..... | 73 |
| Table XX. Univariate correlations between demographic characteristics and the BMQ factor subscales..... | 74 |
| Table XXI. Frequency analysis of the demographic characteristics..... | 80 |
| Table XXII. Drug intake | 81 |
| Table XXIII. Descriptive statistics of the demographic characteristics..... | 82 |
| Table XXIV. Confirmatory factor analysis of the BMQ factor subscales..... | 82 |
| Table XXV. Data adequacy for factor analysis..... | 83 |
| Table XXVI. Descriptive statistics of the BMQ factor subscales..... | 84 |
| Table XXVII. Internal validity of the BMQ factor subscales..... | 84 |
| Table XXVIII. Pearson's correlation coefficient between the BMQ factor subscales..... | 85 |
| Table XXIX. Univariate associations between demographic characteristics and the BMQ factor subscales..... | 85 |
| Table XXX. Univariate correlations between demographic characteristics and the BMQ factor subscales 87 Table XXXI. Results presented in similar studies..... | 90 |
| Table XXXII: Summary of the already presented works in the literature. Correlations with age and number of prescribed medicines..... | 91 |

FIGURES

| | |
|---|----|
| Figure 3.1: Categorization of the methods for adherence quantification..... | 50 |
| Figure 4.1. Patient distribution across beliefs groups..... | 75 |
| Figure 6.1. Patient distribution across beliefs groups..... | 89 |

Corrections:

- At page 45 it should be added, along with the citation 57, the citation 58. The final result will be: "Two other anti-TNF agents, adalimumab and certolizumab pegol, have shown efficacy for the induction and maintenance of remission in Crohn's disease but have not yet been studied in patients with UC [57-58]."
- At page 46, the citation number 58 should be replaced by 59: "...adherence represents the extent that patients follow the advice of healthcare professionals regarding their medication and disease management [59]."
- From there and below, all citation numbers should be increased by one, eg at page 46 the citation 59-60 should be replaced by 60-61: "Typically, about 50% of patients present low adherence to the prescribed treatment [60-61]." That correction follows the whole text until the page 93.

References

(unified format for all references)

- [1] Satsangi J, Jewell DP, Rosenberg WM, Bell JI. Genetics of inflammatory bowel disease. *Gut*. 1994;35(5):696-700.
- [2] Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. *Scandinavian journal of gastroenterology*. 2000;35(10):1075-81.
- [3] Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. *Nature reviews Immunology*. 2008;8(6):458-66.
- [4] D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. *Gastroenterology*. 1998;114(2):262-7.
- [5] Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. *Gastroenterology*. 2004;126(6):1620-33.
- [6] Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(34):13780-5.
- [7] Boyko EJ, Perera DR, Koepsell TD, Keane EM, Inui TS. Effects of cigarette smoking on the clinical course of ulcerative colitis. *Scandinavian journal of gastroenterology*. 1988;23(9):1147-52.
- [8] Kett K, Rognum TO, Brandtzaeg P. Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon. *Gastroenterology*. 1987;93(5):919-24.
- [9] Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. *World journal of gastroenterology : WJG*. 2008;14(3):390-400.
- [10] Bitton A, Sewitch MJ, Peppercorn MA, de BEMD, Shah S, Ransil B, et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. *The American journal of gastroenterology*. 2003;98(10):2203-8.
- [11] Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. *Gastroenterology*. 1994;107(1):3-11.
- [12] D'Haens G, Geboes K, Peeters M, Baert F, Ectors N, Rutgeerts P. Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. *The American journal of gastroenterology*. 1997;92(8):1275-9.
- [13] Both H, Torp-Pedersen K, Kreiner S, Hendriksen C, Binder V. Clinical appearance at diagnosis of ulcerative colitis and Crohn's disease in a regional patient group. *Scandinavian journal of gastroenterology*.

- 1983;18(7):987-91.
- [14] Rao SS, Holdsworth CD, Read NW. Symptoms and stool patterns in patients with ulcerative colitis. Gut. 1988;29(3):342-5.
 - [15] Pera A, Bellando P, Caldera D, Ponti V, Astegiano M, Barletti C, et al. Colonoscopy in inflammatory bowel disease. Diagnostic accuracy and proposal of an endoscopic score. Gastroenterology. 1987;92(1):181-5.
 - [16] Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56(10):1394-403.
 - [17] Samuel S, Bruining DH, Loftus EV, Jr., Thia KT, Schroeder KW, Tremaine WJ, et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2013;11(1):49-54 e1.
 - [18] Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133(5):1670-89.
 - [19] Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. The American journal of gastroenterology. 2006;101(12):2857-65.
 - [20] Kim B, Barnett JL, Kleer CG, Appelman HD. Endoscopic and histological patchiness in treated ulcerative colitis. The American journal of gastroenterology. 1999;94(11):3258-62.
 - [21] Woodruff JM, Hansen JA, Good RA, Santos GW, Slavin RE. The pathology of the graft-versus-host reaction (GVHR) in adults receiving bone marrow transplants. Transplantation proceedings. 1976;8(4):675-84.
 - [22] Lamps LW, Knapple WL. Diverticular disease-associated segmental colitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2007;5(1):27-31.
 - [23] M Economou, G Filis, Z Tsianou, J Alamanos, AKogevinas, K Masalas, A Petrou, E V Tsianos. Crohn's disease incidence evolution in North-western Greece is not associated with alteration of NOD2/CARD15 variants, World J Gastroenterol. 2007;13(38):5116-20.
 - [24] Davies NM. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Diseases of the colon and rectum. 1995;38(12):1311-21.
 - [25] Roys G, Kaplan MS, Juler GL. Surgical management of toxic megacolon. The American journal of gastroenterology. 1977;68(2):161-6.
 - [26] Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut. 1992;33(7):938-41.
 - [27] Lewis JD, Deren JJ, Lichtenstein GR. Cancer risk in patients with inflammatory bowel disease. Gastroenterology clinics of North America. 1999;28(2):459-77, x.
 - [28] Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et

- al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2005;19 Suppl A:5A-36A.
- [29] Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. The American journal of gastroenterology. 2010;105(3):501-23;quiz 24.
- [30] Carter MJ, Lobo AJ, Travis SP, Ibd Section BSoG. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1-16.
- [31] Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571-607.
- [32] Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. The New England journal of medicine. 2001;344(21):1594-602.
- [33] Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled Trial of Sulphasalazine in the Treatment of Ulcerative Colitis. Gut. 1964;5:437-42.
- [34] Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Annals of internal medicine. 1993;118(7):540-9.
- [35] Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. The Cochrane database of systematic reviews. 2006(2):CD000543.
- [36] Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. The American journal of gastroenterology. 1993;88(8):1188-97.
- [37] Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. The American journal of gastroenterology. 1997;92(10):1867-71.
- [38] Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54(7):960-5.
- [39] Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology. 1985;89(5):1005-13.
- [40] Kornbluth A, Marion JF, Salomon P, Janowitz HD. How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic

- review of selected trials. *Journal of clinical gastroenterology*. 1995;20(4):280-4.
- [41] Keller R, Stoll R, Foerster EC, Gutsche N, Domschke W. Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial. *Alimentary pharmacology & therapeutics*. 1997;11(6):1047-52.
- [42] Lofberg R, Ostergaard Thomsen O, Langholz E, Schioler R, Danielsson A, Suhr O, et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. *Alimentary pharmacology & therapeutics*. 1994;8(6):623-9.
- [43] Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. *American journal of human genetics*. 1980;32(5):651-62.
- [44] Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. *Gut*. 2006;55(1):47-53.
- [45] Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. *The American journal of gastroenterology*. 1996;91(3):423-33.
- [46] Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. *Gastroenterology*. 2000;118(6):1025-30.
- [47] Steinhart AH, Baker JP, Brzezinski A, Prokipchuk EJ. Azathioprine therapy in chronic ulcerative colitis. *Journal of clinical gastroenterology*. 1990;12(3):271-5.
- [48] Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. *Annals of internal medicine*. 1989;111(8):641-9.
- [49] Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. *Lancet*. 1996;347(8996):215-9.
- [50] Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *The New England journal of medicine*. 1994;330(26):1841-5.
- [51] Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. *Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association*. 2006;4(6):760-5.
- [52] Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with

- inflammatory bowel disease. *The American journal of gastroenterology*. 2008;103(4):937-43.
- [53] Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. *Gastroenterology*. 1996;110(5):1416-21.
- [54] Mantzaris GJ, Archavlis E, Christoforidis P, Kourteas D, Ambergiadis P, Florakis N, et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. *The American journal of gastroenterology*. 1997;92(3):454-6.
- [55] Fuller R. Probiotics in man and animals. *The Journal of applied bacteriology*. 1989;66(5):365-78.
- [56] Cui HH, Chen CL, Wang JD, Yang YJ, Cun Y, Wu JB, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. *World journal of gastroenterology : WJG*. 2004;10(10):1521-5.
- [57] van Deventer SJ. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab. *Alimentary pharmacology & therapeutics*. 1999;13 Suppl 4:3-8; discussion 38.
- [58] Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. *The New England journal of medicine*. 2005;353(23):2462-76.
- [59] Hawthorne AB, Rubin G, Ghosh S. Medication non-adherence in ulcerative colitis - strategies to improve adherence with mesalamine and other maintenance therapies. *Aliment Pharmacol Ther*. 2008;27:1157-1166.
- [60] McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. *JAMA*. 2002;288:2868-79.
- [61] Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. *Arch Intern Med*. 2007;167:540-50.
- [62] Kane SV, Brixner D, Rubin DT, Sewitch MJ. The Challenge of Compliance and Persistence: Focus on Ulcerative Colitis. *J Manag Care Pharm*. 2008;14(1)(suppl S-a):S2-S12.
- [63] Kane SV, Huo D, Aikens J, Hanauer SB. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. *Am J Med*. 2003;114:39-43.
- [64] Bernick SJ, Kane S. Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence. *Patient Relat Outcome Meas*. Jul 2010;1:57-63.
- [65] Elkjaer M, Shubaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided

- 'Constant-care' approach. Gut 2010;59:1652-61.
- [66] Elkjaer M, Burisch J, Avnstrom S, et al. Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. Eur J Gastroenterol Hepatol 2010;22:695-704.
- [67] Pedersen N, Elkjaer M, Duricova D, Burisch J, Dobrzanski C, Andersen NN, Jess T, Bendtsen F, Langholz E, Leotta S, Knudsen T, Thorsgaard N, Munkholm P. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn's disease. Aliment Pharmacol Ther. 2012;36(9):840-9
- [68] Nigro G, Angelini G, Grossi SB, et al. Psychiatric predictors of noncompliance in inflammatory bowel disease. J Clin Gastroenterol. 2001;32:66-68.
- [69] Luga AO, McGuire M, "Adherence and health care costs", Risk Management and Healthcare Policy. 2014;7:35-44.
- [70] Hawkshead J, Krousel-Wood MA. Techniques for Measuring Medication Adherence in Hypertensive Patients in Outpatient Settings: Advantages and Limitations. Disease Management and Health Outcomes 2007;15:109-118.
- [71] Eaden JA, Abrams K, Mayberry JF. The Crohn's and Colitis Knowledge Score: a test for measuring patient knowledge in inflammatory bowel disease. Am J Gastroenterol, 1999;94:3560e6.
- [72] Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42(3):241-7.
- [73] Hogan, T.P., Awad, A.G., Eastwood, R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol. Med. 1983;13:177-183.
- [74] Morisky, D.E., Green, L.W., Levine, D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care 1986;24(1):67-74.
- [75] Thom DH, Ribisl KM, Stewart AL, et al. Further validation and reliability testing of the Trust in Physician Scale. Med Care 1999;37:510-7.
- [76] Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
- [77] Horne, R., Weinman, J. & Hankins, M. The beliefs about medicine questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychology and Health 1999;14:1-24
- [78] Reilly MC, Gerlier L, Brabant Y, et al. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 2008;30:393-404.
- [79] Irvine EJ, Zhou Q, Thompson AK, et al. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community

- physicians managing inflammatory bowel disease. *Am J Gastroenterol* 1996;91:1571-8.
- [80] Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. *Gut* 1998;43:29-32.
- [81] Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. *J Psychosom Res*. 1999;47(6):555-67.
- [82] Beléndez, M., Hernández, A., Horne, R. & Weinman, J. Evaluación de las creencias sobre el tratamiento: validez y fiabilidad de la versión Españoladel Beliefs about Medicines Questionnaire. *International Journal of Clinical and Health Psychology* 2007;7:767-779.
- [83] A Grant, S Wileman, C Ramsay, L Bojke, D Epstein, M Sculpher, S Macran, M Kilonzo, L Vale, J Francis, A Mowat, Z Krukowski, R Heading, M Thursz, I Russell and M Campbell, "The effectiveness and cost-effectiveness of minimal access surgery amongst people with gastro-oesophageal reflux disease – a UK collaborative study. The reflux trial", *Health Technology Assessment*, 2008;12(31):1-218.
- [84] Komninos I.D., Micheli K., Roumeliotaki T., Horne R. Adaptation and validation of the Beliefs about Medicine Questionnaire (BMQ) in primary care patients in Greece. *European Journal for Person Centered Healthcare* 2012;1(1):224-231.
- [85] Ihara N, Suzuki K, Kurosaki Y, Morita S, Hori K. Factorial invariance of a questionnaire assessing medication beliefs in Japanese non-adherent groups. *Pharm World Sci*. 2010;32(4):432-9.
- [86] Mahler, C., Hermann, K., Horne, R., Jank, S., Haefeli, W.E. & Szecsenyi, J. Patients' Beliefs about Medicines in a primary care setting in Germany. *Journal of Evaluation in Clinical Practice* 2012;18(2):409-413
- [87] Tibaldi, G., Clatworth, J., Torchio, E., Argentero, P., Munizza, C. & Horne, R. The utility of the Necessity-Concerns Framework in explaining treatment non adherence in four chronic illness groups in Italy. *Chronic Illness* 2009;5:129-133.
- [88] Mårdby AC, Akerlind I, Jørgensen T. Beliefs about medicines and self-reported adherence among pharmacy clients. *Patient Educ Couns*. 2007;69(1-3):158-64.
- [89] Perpiñá Tordera, M., Martínez Moragon, E., Belloch Fuster, A., Lloris Bayo, A. & Pellicer Císcar, C. Spanish asthma patients' beliefs about health and medicines: validation of two questionnaires. *Archivos de Bronconeumología* 2009;45:218-223.
- [90] Menckeberg TT, Bouvy ML, Bracke M, Kaptein AA, Leufkens HG, Raaijmakers JA, Horne R. Beliefs about medicines predict refill adherence to inhaled corticosteroids. *J Psychosom Res*. 2008;64(1):47-54.
- [91] Horne R, Cooper V, Gellatly G, Date HL, Fisher M. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and

- adherence: the utility of the necessity-concerns framework. *J Acquir Immune Defic Syndr.* 2007;45(3):334-41.
- [92] Gauchet A, Tarquinio C, Fischer G. Psychosocial predictors of medication adherence among persons living with HIV. *Int J Behav Med.* 2007;14(3):141-50.
- [93] Aikens J.E., Piette J.D. Diabetes patients' medication underuse, illness outcomes, and beliefs about antihyperglycemic and antihypertensive treatments. *Diabetes Care*, 2009;32(1):19-24.
- [94] Fall E., Gauchet A., Izaute M., Horne R., Chakroun N., Validation of the French version of the Beliefs about Medicines Questionnaire (BMQ) among diabetes and HIV patients. *European Review of Applied Psychology*, 2014;64:335-343.
- [95] Kumar K, Gordon C, Toescu V, Buckley CD, Horne R, Nightingale PG, Raza K. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin. *Rheumatology (Oxford)*. 2008;47(5):690-697.
- [96] Treharne GJ, Lyons AC, Kitas GD. Medication adherence in rheumatoid arthritis: Effects of psychosocial factors. *Psychol Health Med.* 2004;9:337-349.
- [97] Neame, R. & Hammond, A. Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. *Rheumatology* 2005;44:762-767.
- [98] Clatworthy, J., Bowskill, R., Parham, R., Rank, T., Scott, J., Horne, R. "Understanding medication non-adherence in bipolar disorders using a Necessity-Concerns Framework". *J Affect Disord* 2009;116: 51-55.
- [99] De las Cuevas, C., Rivero-Santana, A., Perestelo-Pérez, L., González-Lorenzo, M., Pérez-Ramos, J. and Sanz, E.J. Adaptation and validation study of the beliefs about medicines questionnaire in psychiatric outpatients in a community mental health setting. *Human Psychopharmacology: Clinical and Experimental*, 2011;26:140-146.
- [100] Jónsdóttir, H., Friis, S., Horne, R., Pettersen, K.I., Reikvam A. & Andreassen, O.A. Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders. *Acta Psychiatrica Scandinavica* 2009;119:78-84.
- [101] Llewellyn C., Miners A., Lee C., Harrington C., Weinman J. The illness perceptions and treatment beliefs of individuals with severe haemophilia and their role in adherence to home treatment. *Health Psychology* 2003;18: 185-2000.
- [102] Ross S, Walker A, MacLeod MJ. Patient compliance in hypertension: role of illness perceptions and treatment beliefs. *J Hum Hypertens.* 2004;18(9):607-13.
- [103] Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastro-

- oesophageal reflux disease in adult population. Ann Med 1995;27:67–70.
- [104] R.E. O'Carroll, L.M. McGregor, V. Swanson, G. Masterton, P.C. Hayes, "Adherence to Medication After Liver Transplantation in Scotland: A Pilot Study", Liver Transplantation, 2006;12:1862–1868.
- [105] Elkjaer M, Moser G, Reinisch W, Durovicova D, Lukas M, Vucelic B, Wewer V, Colombel JF, Shuhaibar M, O'Morain C, Politi P, Odes S, Bernklev T, Øresland T, Nikulina I, Belousova E, Van der Eijk I, Munkholm P. IBD patients' need in health quality of care ECCO consensus. Journal of Crohn's and Colitis 2008;2(2):181-8.
- [106] Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut, 1996;39(5):690–697.
- [107] Tindall W.N., Boltri J.M., Wilhelm S.M. Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. J Manag Care Pharm, 2007;13(7 suppl A):S2-S12;quiz S13-S14.
- [108] Rubin DT, LoSavio A, Yadron N, Huo D, Hanauer SB. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:1346-50.
- [109] Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-35.
- [110] Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-59.
- [111] van Dongen N, Kaptein AA, "Using patients' experiences with enema design to improve quality of life in patients with IBD", Patient Intelligence, 2013;5:1-14.
- [112] Moshkovska T, Stone MA, Clatworthy J, Smith RM, Bankart J, Baker R, Wang J, Horne R, Mayberry JF., "An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements", Aliment Pharmacol Ther. 2009;30(11-12):1118-27.
- [113] N. Fu, K. Jacobson, A.M. Round, K. Evans, H. Qian, B. Bressler, "The Influence of Adolescent Transition Clinics on the Attitudes and Beliefs in Medicine in Patients With Inflammatory Bowel Disease", Gastroenterology, 2012;146(5):Sup. 1;S-780.
- [114] K. Tsianou, M. G. Tsipouras, N. Giannakeas, K. H. Katsanos, A. Tatsioni, E. C. Karvounis, V. Tsianos, E.s Tsianos and A. T. Tzallas, J. Vlcek, "Beliefs about Medicines Questionnaire (BMQ) in inflammatory bowel disease patients in Greece. Is this useful?", European Journal of Person Centered Healthcare, 2016;4(1):1-9.
- [115] Horne R, Parham R, Driscoll R, Robinson A. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory

- bowel disease. *Inflamm Bowel Dis.* 2009;15(6):837-44.
- [116] UCLA: Statistical Consulting Group, from <http://www.ats.ucla.edu/stat/spss/output/factor1.htm>, (accessed December 22,2014)
- [117] Alhalaiqa F, Masa'Deh R, Batiha AM, Deane K. Validity of Arabic Version of Beliefs About Medication Questionnaire. *Clin Nurs Res.* 2014;1-17.
- [118] Fall E., Gauchet A., zaute M., Horne R., Chakrounc N. *Revue Européenne de Psychologie Appliquée/European Review of Applied Psychology*, 2014;64(6):335-343.
- [119] Russell J, Kazantzis N. Medication beliefs and adherence to antidepressants in primary care. *N Z Med J*, 2008;121(1286):14-20.
- [120] Salgado T, Marques A, Geraldes L, Benrimoj S, Horne R, Fernandez-Llimos F. Cross-cultural adaptation of The Beliefs about Medicines Questionnaire into Portuguese. *Sao Paulo Med J*, 2013;131(2):88-94.
- [121] Sjolander M, Eriksson M, Glader E-L. The association between patients' beliefs about medicines and adherence to drug treatment after stroke: a cross-sectional questionnaire survey. *BMJ Open* 2013;3(9).
- [122] Viktil KK, Frøyland H, Rogvin M, Moger TA. Beliefs about medicines among Norwegian outpatients with chronic cardiovascular disease *Eur J Hosp Pharm Sci Pract*, 2013;21(2):118-120.
- [123] Cesarini M, Katsanos K, Papamichael K, Ellul P, Lakatos PL, Caprioli F, Kopylov U, Tsianos E, Mantzaris GJ, Ben-Horin S, Danese S, Fiorino G. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. *Dig Liver Dis*, 2014;46(2):135-9.